CERS is expected to report earnings to rise 200.00% to -2 cents per share on July 30
Q2'26
Est.
$-0.03
Q1'26
Beat
by $0.04
Q4'25
Est.
$-0.01
Q3'25
Beat
by $0.03
Q2'25
Est.
$-0.03
The last earnings report on April 30 showed earnings per share of 0 cents, beating the estimate of -5 cents. With 1.58M shares outstanding, the current market capitalization sits at 588.08M.
A.I. Advisor
published General Information
General Information
a developer of the INTERCEPT Blood System for platelets and plasma
A.I.dvisor indicates that over the last year, CERS has been loosely correlated with ICUI. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then ICUI could also see price increases.
The Aroon Indicator for CERS entered a downward trend on June 29, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 232 similar instances where the Aroon Indicator formed such a pattern. In of the 232 cases the stock moved lower. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for CERS moved out of overbought territory on July 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CERS as a result. In of 107 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for CERS turned negative on July 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CERS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CERS advanced for three days, in of 224 cases, the price rose further within the following month. The odds of a continued upward trend are .
CERS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.703) is normal, around the industry mean (10.939). P/E Ratio (0.000) is within average values for comparable stocks, (64.127). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.958). CERS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). P/S Ratio (2.607) is also within normal values, averaging (30.558).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CERS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CERS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
